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Introduction
The numbers of patients who suffer from con-
gestive heart failure (CHF) and atrial fibrillation
(AF) are increasing. Recently, there have been ex-
cellent reviews on the problem of AF in patients
with CHF,1,2 and the importance of the problem is
reflected in the steadily rising number of publica-
tions on the topic. Based on a literature search us-
ing MEDLINE, the number of publications regard-
ing AF and CHF increased over the past decade
from nine publications during 1991 to 51 publica-
tions during 2000 (Fig. 1).
AF promotes CHF and vice-versa. This feed-
back loop can result in a downward spiral in many
patients (Fig. 2), that can be interrupted by attack-
ing each problem. This brief review will attempt
to address the interaction between AF and CHF,
atrial pathology and abnormal electrophysiology,
clinical consequences, prognostic importance, and
therapy.
Atrial Pathology and Abnormal
Electrophysiology
CHF results in atrial stretch, atrial fibrosis and
hypertrophy, sympathetic activation, and abnor-
mal electrophysiology, all of which promote the
development of atrial arrhythmias. There has been
much emphasis on the importance of the electri-
cal remodeling that occurs during AF and that pro-
motes recurrent episodes of AF.3 However, electri-
cal remodeling may have less of a role in patients
with CHF. CHF causes a reduction in Ikr and Ica,
which results in an increase in refractoriness and
appears to attenuate the reversible shortening of
atrial refratoriness that occurs during atrial tachy-
cardias.4
Two additional studies have highlighted the
role of the atrial substrate in the promotion of AF
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in the setting of heart failure. Everett et al.5 demon-
strated, in a canine mitral regurgitation model, that
the histological abnormalities that occur during
chronic AF persist following cardioversion, and
that the vulnerability to AF following cardiover-
sion was more dependent on persistent structural
changes than on the reversible abnormal electro-
physiology. Yamada et al.6 showed that abnormal
atrial conduction, manifest as an abnormal P wave
signal-averaged electrocardiogram, was a strong
independent predictor of AF among patients with
CHF (hazard ratio 19).
Clinical Consequences
AF acutely aggravates ventricular perfor-
mance by causing loss of atrial transport. Cardiac
output is often diminished further by the tachycar-
dia that is commonly associated with AF. In ad-
dition, the irregularity of the ventricular rhythm
decreases the cardiac output, independent of the
ventricular rate by approximately 15%.7
AF can also diminish cardiac performance
over time, by creating a tachycardia mediated car-
diomyopathy.8 AF with a rapid ventricular re-
sponse can be the sole etiology of a nonischemic
cardiomyopathy, or it can cause progressive ven-
tricular dysfunction in a patient with a preexist-
ing cardiomyopathy from any cause. Some stud-
ies have shown that patients with AF have a more
rapid deterioration in maximum oxygen consump-
tion over time, compared to patients with sinus
rhythm. These findings argue for a closer follow-
up of these patients.
Prognostic Importance of AF
Although findings regarding the effect of AF
on mortality among heart failure patients have
been conflicting, it is likely that the effect is neg-
ative. A study of 268 ambulatory patients referred
for evaluation of severe heart failure found that AF
was a univariate predictor of event-free survival.9
Although AF was not predictive after multivari-
ate analysis, the sample size was small and the
prevalence of AF was not reported. The Studies
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Figure 1. The number of publications per year on atrial
fibrillation and congestive heart failure over the past
decade.
of Left Ventricular Dysfunction (SOLVD) trial
found that AF was associated with an increase in
all-cause mortality (relative risk 1.34), and progres-
sive pump failure death (relative risk 1.42).10
In the AMIOVIRT trial, which compared
amiodarone to defibrillator implantation among
patients with a nonischemic dilated cardiomyopa-
thy, left ventricular ejection fraction <0.40, and
asymptomatic nonsustained ventricular tachycar-
dia, AF was an independent predictor of death due
to CHF with a relative risk of 4.0.11
Treatment
General Considerations
The three cornerstones of therapy that apply to
AF in general also apply to patients who have both
AF and CHF: prevention of thromboembolism,
ventricular rate control, and maintenance of si-
nus rhythm. CHF increases the likelihood of stroke
during AF, with a relative risk of approximately
1.4.12 Therefore, in the absence of a strong con-
traindication, carefully monitored treatment with
warfarin is mandatory for patients with both AF
and CHF.
Figure 2. Interaction between atrial fibrillation and con-
gestive heart failure.
The more challenging therapeutic dilemma
involves the issue of rate control versus rhythm
control. Patients with CHF are typically the pa-
tients who are most likely to benefit from restora-
tion of atrioventricular synchrony, and yet can be
the most difficult to keep in sinus rhythm. Two re-
cent studies, Atrial Fibrillation Follow-Up Investi-
gation of Rhythm Management (AFFIRM) and Rate
Control versus Electrical Cardioversion (RACE),
found that the approach of rate control is compa-
rable to the approach of maintaining sinus rhythm
in patients with AF.13 However, it is not clear how
these findings apply to patients with symptomatic
heart failure. A new study is underway that plans
to compare rhythm control to rate control, exclu-
sively among patients with CHF.1 In the meantime,
management of patients must be individualized,
taking into account the duration of AF, results of
prior attempts to restore sinus rhythm, likelihood
of maintaining sinus rhythm, ventricular rate, risk
and inconvenience of antiarrhythmic therapy, and
degree of symptoms.
It is important to appreciate the benefits of
standard heart failure therapy in the management
of AF. Digoxin, β-blockers, and angiotensin con-
verting enzyme (ACE) inhibitors are components
of the current optimal pharmacologic therapy for
heart failure. Digoxin is useful in controlling the
resting ventricular rate during AF, and appears to
have a neutral effect on mortality in heart fail-
ure.14 Carvedilol provides ventricular rate con-
trol at rest and during exercise and has been
shown to improve exercise duration in patients
with idiopathic dilated cardiomyopathy and AF.15
Metoprolol may prevent recurrent AF after car-
dioversion.16 Although, there is currently no
strong evidence that ACE inhibitors prevent AF
in patients with CHF, animal studies have found
that ACE inhibition attenuates the effects of pacing
induced heart failure on atrial conduction, atrial
fibrosis, and duration of AF.17
Antiarrhythmic Drug Therapy
Because the recurrence rate after electrical car-
dioversion of AF is high among patients with CHF,
antiarrhythmic drugs are commonly prescribed in
an attempt to maintain sinus rhythm. Because of
proarrhythmia18,19 and worsening of heart fail-
ure20 with the use of sodium channel blockers
in patients with ventricular dysfunction, practice
patterns have shifted toward the use of potassium
channel blockers.
Amiodarone appears to be the most useful an-
tiarrhythmic drug to manage AF in patients with
CHF, and can be safely initiated on an outpatient
basis. The Survival Trial of Amiodarone Therapy
in Congestive Heart Failure (STAT-CHF) trial ran-
domized patients with heart failure to amiodarone
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or placebo, and included 103 patients who were
in AF. A significantly higher number of patients
with AF who were randomized to amiodarone con-
verted to sinus rhythm compared to placebo (31
vs 8%).21 The patients who converted to sinus
rhythm had improved survival compared to those
who remained in AF. Although this finding is in-
triguing, it does not prove that restoration of si-
nus rhythm leads to an improvement in mortality
in patients with heart failure, because patients in
the study with more severe heart disease may have
been less likely to convert to sinus rhythm.
It is tempting to consider d,l-sotalol as an al-
ternative to amiodarone for the treatment of AF in
patients with heart failure, given the low risk of
organ toxicity compared to amiodarone, and the
benefits of β-blockade in heart failure. However,
there are little data to support the use of sotalol in
the presence of symptomatic ventricular dysfunc-
tion, and there is evidence that the risk of proar-
rhythmia from sotalol due to torsades de pointes is
increased in the presence of CHF.22 Furthermore,
a recent study found amiodarone to be twice as
effective as sotalol in maintaining sinus rhythm.23
This study, however, did not include patients with
New York Heart Association (NYHA) class III or IV
heart failure symptoms.
Dofetilide has been shown to be safe and ef-
fective in restoring sinus rhythm in patients with
CHF. In the Danish Investigations of Arrhythmia
and Mortality on Dofetilide (DIAMOND) substudy,
dofetilide was associated with a higher AF conver-
sion rate compared to placebo (59 vs 34%).24 How-
ever, the use of dofetilide is problematic because it
must be initiated in the hospital, requires careful
monitoring of the QT interval to reduce the risk of
torsades de pointes, and, in the United States, can
only be prescribed by an approved physician.
Nonpharmacologic Therapy
Several nonpharmacologic therapies are avail-
able for the management of AF in patients with
CHF. For patients in whom the ventricular rate
cannot be controlled and sinus rhythm cannot be
maintained, catheter ablation or modification of
the atrioventricular junction has been shown to
improve symptoms, and often improves ventric-
ular function.25 The advantages of atrioventricu-
lar node modification, compared to complete abla-
tion, include cost savings,26 minimization of pace-
maker dependency, and avoidance of the adverse
hemodynamic effects associated with right ven-
tricular pacing. However, complete ablation and
pacemaker implantation is more commonly per-
formed, because it is more definitive and elimi-
nates the irregularity of the ventricular rhythm.
More work is need to develop techniques, like His-
bundle pacing27 and electrical vagal stimulation
that control the ventricular rate and preserve nor-
mal His-Purkinje activation.
Nonpharmacologic options for rhythm control
include catheter ablation, the surgical maze proce-
dure, an implantable atrial defibrillator, and mul-
tisite pacing. Much of the experience with seg-
mental pulmonary vein ablation has been with
patients who have minimal structural heart dis-
ease.28 It is possible that the pulmonary veins are
less important in the genesis of AF in patients with
CHF. In addition, segmental pulmonary vein iso-
lation appears to be less useful in the presence
of persistent compared to paroxysmal AF.28 Other
atrial ablation options like circumferential pul-
monary vein isolation may be more useful for pa-
tients with structural heart disease and persistent
AF.29
Conclusion
CHF and AF interact to create a downward spi-
ral that adversely affects functional capacity and
longevity. Until trials that compare rate control
to rhythm control among patients with CHF have
been completed, treatment decisions must be in-
dividualized. To be effective, treatment aimed at
maintaining sinus rhythm must address the abnor-
mal atrial substrate associated with CHF, which ap-
pears to be an important factor in the development
of AF in these patients.
Antiarrhythmic drugs to maintain sinus
rhythm should be limited to amiodarone and
dofetilide. Given the limitations of drug therapy in
the treatment of AF in patients with CHF, nonphar-
macologic therapies need to be explored further.
Atrioventricular junction ablation can be useful
for patients whose ventricular rate cannot be con-
trolled. Better nonpharmacologic techniques are
needed to maintain sinus rhythm and to control
the ventricular rate during AF, while preserving
normal ventricular activation.
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